ADC Target Strategy Radar

Oncology Edition

Map a curated ADC oncology target universe by clinical crowding, clinical maturity, sponsor competition, patent-density signals, and recent momentum.

Built from ClinicalTrials.gov and a conservative patent-signal layer. Outputs are designed to help teams prioritize which ADC targets deserve expert IP and BD attention — not to replace FTO analysis or target-selection advice.

Open methodology Request custom ADC target scan

Targets tracked

20

Curated oncology ADC target-modality pairs in the current public screen.

Linked ADC trials

396

ClinicalTrials.gov records linked into the current public target map.

Active or recruiting

247

Active trial count aggregated across the tracked target universe.

Unique sponsors

193

Distinct sponsors mapped into the target screen.

Patent-density signals

7

Signal records from the modular patent layer and local fallback sample.

Manual review required

0

Targets currently flagged for lower-confidence or ambiguous public signals.

Target strategy table

Public target screen

Target	Strategy	Crowding	Maturity	Patent density	Momentum	Active trials	Sponsors	Confidence
HER2 / ERBB2	Emerging Competitive	High	Phase 1 Only	Low	Rising	100	82	High
TROP2 / TACSTD2	Emerging Competitive	High	Phase 1 Only	Low	Rising	41	31	High
Nectin-4 / NECTIN4	Emerging Competitive	High	Phase 1 Only	Low	Rising	17	16	High
B7-H3 / CD276	Emerging Competitive	High	Phase 1 Only	Low	Rising	18	12	High
CLDN18.2 / Claudin 18.2	Emerging Competitive	Elevated	Phase 1 Only	Low	Rising	3	6	High
FRα / FOLR1 / Folate receptor alpha	Emerging Competitive	High	Phase 1 Only	Low	Rising	8	10	High
EGFR	Emerging Competitive	High	Phase 1 Only	Low	Rising	15	21	High
c-MET / MET	Emerging Competitive	High	Phase 1 Only	Low	Rising	29	45	High
ROR1	Clinically Active Patent Light	Elevated	Phase 1 Only	Low	Watch	3	4	High
GPC3	Early Watch	Low	Phase 1 Only	Low	Watch	1	1	High
PSMA / FOLH1	Low Public Signal	Low	Phase 1 Only	Low	Quiet	0	0	High
CD30 / TNFRSF8	Clinically Active Patent Light	Elevated	Phase 1 Only	Low	Quiet	2	3	High
CD33	Low Public Signal	Low	Phase 1 Only	Low	Quiet	0	0	High
CD79b	Low Public Signal	Low	Phase 1 Only	Low	Quiet	0	0	High
BCMA / TNFRSF17	Early Watch	Low	Phase 1 Only	Low	Watch	2	2	High
MUC1	Low Public Signal	Low	Phase 1 Only	Low	Quiet	0	0	High
NaPi2b / SLC34A2	Early Watch	Low	Phase 1 Only	Low	Watch	1	2	High
DLL3	Emerging Competitive	Elevated	Phase 1 Only	Low	Rising	7	2	High
LIV-1 / SLC39A6	Low Public Signal	Low	Phase 1 Only	Low	Quiet	0	0	High
PTK7	Low Public Signal	Low	Phase 1 Only	Low	Quiet	0	1	High

Fast-emerging targets

Momentum-led watchlist

HER2 / ERBB2: HER2 / ERBB2 is flagged as emerging competitive based on 100 active trials across 82 sponsors and 1 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
TROP2 / TACSTD2: TROP2 / TACSTD2 is flagged as emerging competitive based on 41 active trials across 31 sponsors and 1 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Nectin-4 / NECTIN4: Nectin-4 / NECTIN4 is flagged as emerging competitive based on 17 active trials across 16 sponsors and 0 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
B7-H3 / CD276: B7-H3 / CD276 is flagged as emerging competitive based on 18 active trials across 12 sponsors and 1 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
CLDN18.2 / Claudin 18.2: CLDN18.2 / Claudin 18.2 is flagged as emerging competitive based on 3 active trials across 6 sponsors and 0 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.

Patent-heavy but clinically light

Signals to review cautiously

Mature late-stage targets

Established programs

Sponsor-target matrix

Sponsor views

AbbVie: 3 tracked targets
AbGenomics B.V Taiwan Branch: 1 tracked targets
Academic and Community Cancer Research United: 1 tracked targets
ADC Therapeutics S.A.: 1 tracked targets
Adrienne G. Waks: 1 tracked targets
Akeso: 1 tracked targets

Methodology teaser

Conservative labeling only

Strategy labels are deterministic summaries of public registry and patent-density metadata patterns. They are not conclusions about legal position, clinical superiority, or commercial attractiveness.

ADC access

Receive ADC Target Updates by Email

Use this form to compare two ADC targets, subscribe for email updates, choose CSV interests, track one target monthly, or request a tumor-type-specific cut.